In fluctuating Parkinson's disease (PD) patients, treatment of PD using the catechol-O-methyl transferase inhibitor entacapone with carbidopa/levodopa improves quality of life and activities of ...

Levodopa-induced dyskinesia (LID) is a common complication after dopamine-replacement therapy in Parkinson's disease. The neural mechanisms underlying LID are far from clear, although significant ...

Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...

VYALEV offers a non-surgical alternative that provides continuous levodopa delivery throughout the day and night. The pivotal study demonstrated that patients with advanced Parkinson’s disease ...

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

Foscarbidopa and foslevodopa are pro-drugs for carbidopa and levodopa, which are standard-of-care Parkinson's treatments. The new treatment, formerly know as ABBV-951, is the first subcutaneous 24 ...

for adults living with advanced Parkinson's disease (PD). Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in ...

The therapy is delivered as a 24-hour continuous infusion to treat motor fluctuations in adults with advanced Parkinson’s. AbbVie already markets a carbidopa and levodopa combination with Duopa.

AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of ...

A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...

Parkinson's disease, a degenerative brain condition ... "These can be extremely effective for years and include dopamine (Levodopa) and related medications for the movement symptoms." ...

“For too long, the Parkinson’s community has had limited treatment ... compared with oral immediate-release ...